"If you’re committed to advancing the quality and availability of medical care, you and I share a common objective. I’m looking for entrepreneurs that are changing the face of health care by combining vision and innovation with sound planning and leadership."
Nina's Latest Buzz
Nina has been part of InterWest's healthcare team since 2002, investing in in biopharmaceuticals and healthcare IT. Nina has a particular interest in the transformation of the U.S. healthcare system and invests in opportunities that serve high unmet medical needs and align with improved health outcomes at lower cost.
She is a board member of Alvine Pharmaceuticals, Cebix, Cidera Therapeutics, Eiger Biopharmaceuticals, Lycera, Ocera (OCRX) and Welltok. Nina lend InterWest's investment in Alt12 and co-sponsored InterWest's investment in TESARO (TSRO). She also leads InterWest's initiative in healthcare IT, bridging InterWest's healthcare and IT sector teams. Nina is co-chair of ConsumerMed.org, a forum to address the convergence of healthcare and consumer innovation, and serves as a mentor to the Nike+ Accelerator and to Blueprint Health.
Prior to joining InterWest, Nina was an investment manager at Bay City Capital, a life sciences merchant bank, and a research associate at Oracle Partners, a healthcare-focused hedge fund. Nina began her career conducting health policy and survey research with the Kaiser Family Foundation.
Nina received a B.A. in human biology from Stanford University with a focus on health policy and bioethics.
Aspreva Pharmaceuticals (IPO 2006, ASPV), CNS Therapeutics (Acquired by Covidien in 2012), Fluidigm (IPO 2011, FLDM), Labrys Biologics (Acquired by Teva Pharmaceuticals, TEVA, in 2014), NovaCardia (Acquired by Merck in 2007), Trius Therapeutics (TSRX; Acquired by Cubist in 2013)
I've always known that my career would focus on medicine and the life sciences as I am committed to advancing health care technologies and improving access to care. At InterWest, I aim to implement an investment strategy that integrates market vision and technical innovation with sound business planning and leadership. In so doing, it is my objective to partner with the entrepreneurs and scientists working to change the face of health care.